CN101361885A - Chinese traditional medicine composition for treating the prostatitis and preparation method thereof - Google Patents
Chinese traditional medicine composition for treating the prostatitis and preparation method thereof Download PDFInfo
- Publication number
- CN101361885A CN101361885A CNA2008101675051A CN200810167505A CN101361885A CN 101361885 A CN101361885 A CN 101361885A CN A2008101675051 A CNA2008101675051 A CN A2008101675051A CN 200810167505 A CN200810167505 A CN 200810167505A CN 101361885 A CN101361885 A CN 101361885A
- Authority
- CN
- China
- Prior art keywords
- group
- preparation
- fructus
- filter
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine preparation used for curing diseases of prostate and a preparation method thereof. The preparation is made from the active drug ingredients processed by mulberry syncarp, Gorgon fruit, Sevenlobed Yam Rhizome, cherokee rose and cape jasmine and a pharmaceutically acceptable carrier according to a certain proportion by processing. The carrier is starch. Compared with the prior art, the traditional Chinese medicine preparation provided by the invention has obvious curative effects when being used for treating prostatitis and hyperplasia of prostate gland.
Description
Technical field
A kind of Chinese medicine preparation that is used for the treatment of prostatosis and preparation method thereof belongs to technical field of traditional Chinese medicine pharmacy.
Technical background
Prostatic hyperplasia is a kind of commonly encountered diseases, the frequently-occurring disease of elderly men, and sickness rate increases gradually with age growth.It mainly shows: frequent micturition, dysuria, acute urine retention or urinary incontinence; Often only be the nocturia increased frequency in early days, then as seen urine is anxious, hot, puckery, bitterly as concurrent infection, or with hematuria etc., and severe patient must urethral catheterization or taked operative treatment; Prostatitis also is the urology department commonly encountered diseases, frequently-occurring disease.Acute stage, mainly show as urgent micturition, frequent micturition, dysurea, meeting pain over the perineum, and very General Symptomies such as fever with aversion to cold appear in the person.There is sense of discomfort in the chronic few abdomen perineal testis portion that then shows as, and normal adularescent secretions overflows in the urethra, is common in the prime of life among the male.Diseases such as lumbago, edema, hypertension can appear in severe patient.
Prostatitis, prostatic hyperplasia are the commonly encountered diseases of male genitourinary system, the sickness rate height, and claim rejuvenation trend gradually.Modern medicine is in the treatment prostatosis, though method is many, curative effect is dissatisfied.Its main cause: 1. cause of disease complexity often is difficult in clinical clear and definite.2. pathological change is many with the retention of gland liquid, and inflammation parcel and slim fiber turn to the master.3.McNcal (1972) think on the prostate anatomy the perimeter region glandular tube and urethra meets at right angles even bevel, be unfavorable for the eliminating of secretions, and cause easily that urine is counter to flow.4. inflammatory EPS-PH value increases and is alkalescence, is unfavorable for that medicine permeates in prostate, and many adverse effects have increased very big difficulty to treatment.This sick cause of disease, pathology complexity, course of disease delay, obstinate Nan More, aspect clinical treatment, lack effective medicine and method both at home and abroad always, bring very big misery to patient, therefore, the active drug of development treatment prostatitis, prostatic hyperplasia has the good application development prospect, will produce remarkable social benefit and economic benefit.
At the existing defective of present state of the art, by excavating the abundant natural resources of Chinese medicinal materials of motherland, in conjunction with a large amount of traditional Chinese medical science prescription theories and clinical pharmacodynamic experiment, we have invented a kind of prescription and have constituted clear and definite, technology is simple, for prostatitis, prostatic hyperplasia Chinese medicine preparation evident in efficacy.
Summary of the invention
The purpose of this invention is to provide a kind of is raw material with the Chinese herbal medicine, and prostatitis, prostatic hyperplasia are had better therapeutic effect, and Chinese medicine preparation without any side effects.
Another purpose of the present invention provides a kind of Chinese medicinal preparation method for the treatment of prostatitis, prostatic hyperplasia.
The present invention is achieved in that
Component is calculated by weight, and pharmaceutical composition of the present invention is to be prepared from by following materials of weight proportions:
300 parts of 450 parts of Rhizoma Dioscoreae Septemlobaes of 450 portions of Semen Euryaless of Fructus Mori
100 parts of 200 parts of Brassica campestris L pollens of 250 portions of Fructus Gardeniaes of Fructus Rosae Laevigatae
The preparation method of preparation of the present invention: get Fructus Mori, Semen Euryales, Fructus Rosae Laevigatae, Fructus Gardeniae four flavors, decoct with water 3 times, each decocted first, second time 2 hours with 8 times of water gagings, the 3rd time collecting decoction left standstill with 6 times of water gagings decoctions 1 hour, filter, filtrate decompression concentrate (0.08Mpa, 80 ℃) to the volume of crude drug than (1:1), standby; Rhizoma Dioscoreae Septemlobae is ground into coarse powder, adds 10 times of amount alcohol reflux 3 times, each 1 hour, filters, merging filtrate merges with above-mentioned reserve liquid, and adding ethanol is 70% to containing the alcohol amount, left standstill 24 hours, and filtered, filtrate recycling ethanol to relative density is 1.30～1.35 (80 ℃), 60 ℃ of dryings are ground into fine powder, and Brassica campestris L pollen was pulverized 100 mesh sieves, with the abundant mixing of above-mentioned medicated powder, add appropriate amount of starch or dextrin, mixing, granulate, drying gets preparation of the present invention.
Prostatic hyperplasia and prostatitis belong to motherland's medical science " difficulty in urination " and reach " pyretic stranguria " " stranguria caused by overstrain " category, the main etiology and pathogenesis of " difficulty in urination " is: 1, the pungent savoury of damp-heat accumulation surfeit, make living damp and hot, damp and hot puzzled, the bladder of making a bet, functioning of bladder is unfavorable and be the difficulty in urination.2, the lung-heat with QI-obstruction a variety of causes causes lung-heat stop up to be contained, and the lung being the upper source of fluids, lung-heat are contained and can not regulating fluid apssage, and subordinate's bladder forms the difficulty in urination.3, the insufficiency of the spleen clearing heat in QI system of spleen-QI failing to rise up can not rise, and then turbid yin is difficult to descend, urine thereby unfavorable.4, stagnation of QI due to depression of the liver depression of liver-QI, catharsis is too late, thereby influences the operation and the gasification function of three warmers water liquid, causes the logical accent of water channel to be obstructed, and forms the difficulty in urination.5, urinary tract obstruction blood stasis loses essence, or the lump calculus, blocks urinary tract, and difficulty in urination is to discharge thereby to form the difficulty in urination.The etiology and pathogenesis of stranguria is: 1, damp-heat in the urinary bladder: the product of the hot delicious food of polyphagia, or be addicted to drink too, lead to damp and hot, the bladder of making a bet; Or down cloudy unclean, foul heresy invaded bladder, lead to damp and hot, and be pouring.2, deficiency of spleen and stomach drenches the end more for a long time, and damp and hot consumption is hindered healthy energy, or old, eipathia asthenia, and overworks, and chamber does not save, and all can cause deficiency of spleen and stomach.Insufficiency of the spleen then sinking of QI of middle-JIAO, the then instability of kidney-QI of suffering from a deficiency of the kidney, thereby dribbling urination is endlessly.3, stagnation of QI due to depression of the liver: angry impairing the liver, the stagnation of QI is not declared, and stagnated QI transforming into fire, or the gas fire stagnation influences the gasification of bladder in the part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels, then lacks abdomen and expands urinate involved and abstruse and bitterly, and the heeltap and is a qi stranguria not to the utmost.
We are applicable to the prostatosis of the two void of spleen kidney, damp and hot multiple abscess.Fructus Mori in the side: nourishing YIN and supplementing blood, the intestine moistening of promoting the production of body fluid; Semen Euryales invigorating the spleen to arrest diarrhea, supplementing the kidney to control the nocturnal, astringent therapy leukorrhagia stopping are monarch drug.Brassica campestris L pollen has the adjusting male endocrine, recovers bladder urethral smooth muscle function; Fructus Gardeniae: let out fiery relieving restlessness, clearing away heat-damp and promoting diuresis, removing pathogenic heat from blood and toxic substance from the body; Dioscorea septemloba Thunb. is separated: it is ministerial drug at etiological treatment jointly that dampness removing goes turbid, expelling wind and removing dampness, three.Fructus Rosae Laevigatae: controlling nocturnal emission with astringent drugs reducing urination, relieving diarrhea with astringents, the effect that strengthens monarch drug is an adjuvant drug.The merit that full side plays invigorating the kidney and spleen, clearing away heat-damp and promoting diuresis, controlling nocturnal emission with astringent drugs reducing urination altogether.
For confirming that product of the present invention has effective therapeutic effect, we have carried out a series of pharmacodynamic studies;
Now, its main pharmacodynamics is described with capsule contrast XIPAYIMAIZIBIZI KOUFUYE of the present invention:
The experiment medicine:
Capsule of the present invention is the medicine of the embodiment of the invention 1 method preparation.
XIPAYIMAIZIBIZI KOUFUYE is to buy on the market.
One, to the inhibitory action of rat bacterial prostatitis
60 of SD male rats, body weight 300～350g is divided into 6 groups at random, and 10 every group, normal control group and model group are irritated the normal saline of stomach with volume; Capsules group of the present invention is gastric infusion 0.4,0.8,1.6g crude drug/kg respectively; XIPAYIMAIZIBIZI KOUFUYE group gastric infusion 1.6g crude drug/kg.Successive administration 7d, 4d after administration is after the lumbar injection pentobarbital sodium 45mg/kg anesthesia, at the aseptic condition median incision of lower abdomen, in the prostate abdominal part, injection 1.4 * 107CFU/ml escherichia coli normal saline suspension 0.1ml, normal control group injecting normal saline, putting into cage after the stitching raises, animal continues administration after the modeling, and puts to death after the 7d administration, cuts open the belly rapidly, get massage of prostate liquid and measure leukocyte count, other gets a smear and carries out the inspection of lecithin density.See Table 1
The influence of table 1 pair prostatitis rat lecithin density and total white blood cells (x ± s)
Compare * * P＜0.01 with model group; With the XIPAYIMAIZIBIZI KOUFUYE group than △ P＜0.05, #P 0.05.
The result: Capsules group of the present invention and XIPAYIMAIZIBIZI KOUFUYE group have the obvious suppression effect to the rat bacterial prostatitis, can improve lecithin density in the prostate, reduce leukocyte count, have compared significant difference with model group.Capsules group of the present invention is stronger to the inhibitory action of rat bacterial prostatitis than XIPAYIMAIZIBIZI KOUFUYE group.
Two, the influence of xylol induced mice auricle edema
50 of Male Kunming strain mice, body weight 18～22g is divided into 5 groups at random, 10 every group.Matched group is irritated the normal saline of stomach with volume; Capsules group of the present invention is gastric infusion 0.8,1.6,3.2g crude drug/kg respectively; XIPAYIMAIZIBIZI KOUFUYE group gastric infusion 3.2g crude drug/kg.Successive administration 7d, every day 1 time, behind the last administration 1h, only be applied to two sides inside and outside the auris dextra with 100% dimethylbenzene 0.5ml/, left side ear is not done any processing, behind the 1h animal etherization is put to death, ears are laid round auricle respectively with 6mm diameter macropore device under subtracting at the same position of mice, and electronic analytical balance is weighed.With the mice ear degree as acutely inflamed swelling index (mice ear degree=auris dextra sheet weight-left auricle weight) due to the dimethylbenzene.See Table 2
The influence of swelling due to the table 2 pair Mice Auricle dimethylbenzene (x ± s)
Compare * * P＜0.01 with matched group; With the XIPAYIMAIZIBIZI KOUFUYE group than △ P＜0.05, #P 0.05.
The result: the control group mice auris dextra is obviously red and swollen, and thickness increases, and auricle swelling degree is big.Capsules group of the present invention and XIPAYIMAIZIBIZI KOUFUYE group all can obviously suppress dimethylbenzene induced mice ease auricle swelling, have compared significant difference with matched group.Capsules group of the present invention is stronger than the antiinflammatory action of XIPAYIMAIZIBIZI KOUFUYE group.
Three, analgesic activity
50 of Kunming male mices, body weight 18～22g is divided into 5 groups at random, 10 every group.Matched group is irritated the normal saline of stomach with volume; Capsules group of the present invention is gastric infusion 0.8,1.6,3.2g crude drug/kg respectively; XIPAYIMAIZIBIZI KOUFUYE group gastric infusion 3.2g crude drug/kg.Successive administration 3d, behind the last administration 1h, the equal lumbar injection 0.8% acetic acid 0.2ml/ of every Mus, mouse writhing number of times in the record 20min, and calculate each and organize analgesia percentage rate.See Table 3
The influence of table 3 Dichlorodiphenyl Acetate induced mice writhing response (x ± s)
Compare * * P＜0.01 with matched group; With the XIPAYIMAIZIBIZI KOUFUYE group than △ P＜0.05, #P 0.05.
The result: Capsules group of the present invention and XIPAYIMAIZIBIZI KOUFUYE group all make the acetic acid induced mice turn round the minimizing of body number of times, dose-effect reaction relation is preferably arranged,, turn round the body number of times and reduce along with the increasing of dosage, it is inhibited that the Dichlorodiphenyl Acetate induced mice is turned round body, compares the difference that significance is arranged with matched group.Capsules group of the present invention is stronger than the analgesic activity of XIPAYIMAIZIBIZI KOUFUYE group.
Four, diuresis
50 of SD male rats, body weight 180～220g is divided into 5 groups at random, 10 every group.Matched group is irritated the normal saline of stomach with volume; Capsules group of the present invention is gastric infusion 0.4,0.8,1.6g crude drug/kg respectively; XIPAYIMAIZIBIZI KOUFUYE group gastric infusion 1.6g crude drug/kg.Successive administration 7d is after the last administration, by urine in the 2h behind the rat metabolic cage laboratory method collection medicine.See Table 4
The influence of table 4 pair rat urine amount (x ± s)
Compare * * P＜0.01 with matched group; With the XIPAYIMAIZIBIZI KOUFUYE group than △ P＜0.05, #P 0.05.
The result: Capsules group of the present invention and XIPAYIMAIZIBIZI KOUFUYE group to rat after administration in the 2h urine amount obviously increase, compared significant difference with matched group.Capsules group of the present invention is stronger to the diuresis of rat than XIPAYIMAIZIBIZI KOUFUYE group.
Five, function of promoting blood circulation to disperse blood clots
60 of SD rats, male and female half and half, body weight 180～220g is divided into 6 groups at random, 10 every group.Normal control group and model group are irritated the normal saline of stomach with volume; Capsules group of the present invention is gastric infusion 0.4,0.8,1.6g crude drug/kg respectively; XIPAYIMAIZIBIZI KOUFUYE group gastric infusion 1.6g crude drug/kg.Successive administration 7d, 3h after the last administration, except that the normal control group, all the other respectively organize subcutaneous injection 0.1% adrenalin hydrochloride injection 0.08ml/100g, totally 2 times, interval 4h, (each interval 2h of front and back) puts into frozen water 5min with rat between double injection, disposes the back fasting, next day, each treated animal carotid artery is got each value of hematometry hemorheology.See Table 5
The influence of table 5 pair hemorheology of rat (x ± s)
Compare * * P＜0.01 with model group; With the XIPAYIMAIZIBIZI KOUFUYE group than △ P＜0.05, #P 0.05.
The result: Capsules group of the present invention and XIPAYIMAIZIBIZI KOUFUYE group can reduce whole blood viscosity and plasma viscosity, have the effect that improves hemorheological property, have compared significant difference with model group.Capsules group of the present invention is stronger than XIPAYIMAIZIBIZI KOUFUYE group function of promoting blood circulation to disperse blood clots.
Six, the influence that rat Intradermal blood vessel due to histamine, 5 one hydroxytryptamines is oozed out
Get 50 of healthy male Witar rat, body weight 200～240g is divided into 5 groups at random, 10 every group.Matched group is given physiology salt 20ml/kg; Capsules group of the present invention administration 0.4,0.8 respectively, 1.6g crude drug/kg; XIPAYIMAIZIBIZI KOUFUYE group administration 1.6g crude drug/kg, each organizes equal lumbar injection, behind the 30min.Etherization, at upper and lower 2 depilations place difference of rat back subcutaneous injection histamine, 5 one hydroxytryptamine 0.1ml (0.1 μ g), inject 1% ivens basket 4ml/kg through femoral vein immediately, behind the 15min, sacrificed by decapitation is cut the upper and lower two place's indigo plants in back and is dyed skin, is immersed in respectively after shredding in 5ml acetone one water (7:3) solution, centrifugal behind the 48h, get supernatant.With 722 type spectrophotometers, measure absorbance in wavelength 610nm place.See Table 6
The influence that rat Intradermal blood vessel oozes out due to table 6 pair histamine, 5 one hydroxytryptamines (x ± s)
Compare * * P＜0.01 with matched group; With the XIPAYIMAIZIBIZI KOUFUYE group than △ P＜0.05, #P 0.05.
The result: Capsules group of the present invention and XIPAYIMAIZIBIZI KOUFUYE group have the obvious suppression effect to the inflammatory reaction that allergin (histamine, 5 one hydroxytryptamines) causes, have inhibitory action, compared significant difference with matched group to non-specific inflammatory reaction.Capsules group of the present invention is stronger to non-specific inflammatory reaction inhibition than XIPAYIMAIZIBIZI KOUFUYE group.
Seven, the mouse retention gential sinus is implanted the influence of prostatic hyperplasia model
50 of Kunming kind male white mouses, body weight 28～30g, under 1% pentobarbital sodium 60mg/kg intraperitoneal anesthesia, the sterile working opens hypogastric region, careful separation prostate siphonal lobe, tweezers with sharp tip are implanted into the urogenital sinus tissue of three 16d gestational ages with the strain Mus to the prostate siphonal lobe, check to confirm to sew up stomach wall immediately after the implantation; Other gets 10 of mices, the prostate siphonal lobe is visited with syringe needle stung three times as sham operated rats.Behind the 24h modeling mice is divided into 5 groups at random, 10 every group, sham operated rats and model group are irritated the normal saline of stomach with volume; Capsules group of the present invention is gastric infusion 0.8,1.6,3.2g crude drug/kg respectively; XIPAYIMAIZIBIZI KOUFUYE group gastric infusion 3.2g crude drug/kg.Successive administration 30d, every day 1 time, 24h puts to death animal behind the last medicine, wins the prostate siphonal lobe, claims weight in wet base (mg), calculates organ index (mg/10g body weight).See Table 7
The influence of table 7 mouse retention gential sinus implantation prostatic hyperplasia model (x ± s)
Compare * * P＜0.01 with model group; With the XIPAYIMAIZIBIZI KOUFUYE group than △ P＜0.05, #P 0.05.
The result: Capsules group of the present invention and XIPAYIMAIZIBIZI KOUFUYE group are implanted weight of prostate of prostatic hyperplasia mice and the effect that index has obvious reduction to urogenital sinus, have compared significant difference with matched group.Capsules group of the present invention is implanted the pathological change of bringing out the mice prostatic hyperplasia model than XIPAYIMAIZIBIZI KOUFUYE group to urogenital sinus and is alleviated the effect enhancing.
Eight, to the prostatitic influence of rat fibroplasia due to the xiaozhiling injection
60 of SD male rats, body weight 180～220g is divided into 6 groups at random, 10 every group.Under aseptic condition, take off the through abdominal cavity of the about 1cm of abdominal part median incision behind the etherization, propose bladder and both sides seminal vesicle, expose the prostate notopodium that is attached to the seminal vesicle inboard, again 25% XIAOZHILING ZHUSHEYE 0.2mL is injected prostate bilateral notopodium respectively, suture muscles then, skin.Normal control group and model group are irritated the normal saline of stomach with volume; Capsules group of the present invention is gastric infusion 0.4,0.8,1.6g crude drug/kg respectively; XIPAYIMAIZIBIZI KOUFUYE group gastric infusion 1.6g crude drug/kg.Every day 1 time, successive administration 30d, 1h after the last administration, the sacrificed by decapitation rat is got whole notopodiums of prostate and siphonal lobe, claims its weight in wet base, calculates the acropetal coefficient, and gets injection point peripheral part prostata tissue, carries out histological examination.See Table 8
The prostatitic influence of rat fibroplasia due to the table 8 pair xiaozhiling injection (x ± s)
Compare * * P＜0.01 with model group; With the XIPAYIMAIZIBIZI KOUFUYE group than △ P＜0.05, #P 0.05.
The result: Capsules group of the present invention and XIPAYIMAIZIBIZI KOUFUYE group all can alleviate weight of prostate to some extent, and can alleviate the cell infiltration in the lumen of gland significantly, have compared significant difference with matched group.Capsules group of the present invention is stronger than the prostatitic effect of rat fibroplasia due to the XIPAYIMAIZIBIZI KOUFUYE group antagonism xiaozhiling injection.
Nine, to the influence of experimental prostatic hyperplasia model rat
60 of SD male rats, body weight 220～260g is divided into 6 groups at random, 10 every group.Getting one group at random is the normal control group, and all the other 5 groups are carried out modeling, every rat subcutaneous injection every day testosterone propionate 3mg/kg, 25d continuously.From modeling 1d, normal control group and model group are irritated the normal saline of stomach with volume; Capsules group of the present invention is gastric infusion 0.4,0.8,1.6g crude drug/kg respectively; XIPAYIMAIZIBIZI KOUFUYE group gastric infusion 1.6g crude drug/kg.Every day 1 time, continuous 25d, 24h after the last administration, after every group of rat divided its body weight of another name, the common carotid artery intubate was got blood, and separation of serum is measured Zn in the prostate serum
2+The activity of content and acid phosphatase (PACP).See Table 9
Zn in the table 9 pair prostatic hyperplasia rat blood serum
2+The active influence of content and PACP (x ± s)
Compare * * P＜0.01 with model group; With the XIPAYIMAIZIBIZI KOUFUYE group than △ P＜0.05, #P 0.05.
The result: Capsules group of the present invention and XIPAYIMAIZIBIZI KOUFUYE group can obviously suppress activity and the zn of PACP in the hypertrophy rat blood serum of experimental prostatitis
2+Content, have and suppress the prostatic proliferative effect of experimental rat, with model group utmost point significant difference is arranged more all.Capsules group of the present invention is stronger to the effect of anti-prostatic hyperplasia than XIPAYIMAIZIBIZI KOUFUYE group.
Acute toxicity testing is the result show: with capsule Cmax of the present invention, maximum volume gastric infusion, successive administration is 3 times in 24h, each 4h at interval, and accumulation medicine total amount reaches 65g/kg, is equivalent to 328 times of clinical plan consumption.In the 7d, mice activity, feed, drainage are all normal after the administration, well-grown, and the hair color light, its average body weight average increases with the prolongation of test period.8d puts to death every mice perusal heart of back dissection, liver, spleen, lung, kidney, brain, thymus, adrenal gland, uterus, stomach, intestinal etc. and does not all find color and paramophia.Show that this capsule does not have acute toxic reaction.
Long term toxicity test is the result show: capsule of the present invention is divided into that basic, normal, high dosage is respectively 4,8,16g/kg/d, be equivalent to 20.2,40.4,80.8 times of clinical dosage, gastric infusion is after 12 weeks, capsule of the present invention does not all have tangible influence, the yet no abnormal pathological change of system's dissection, organ coefficient and histopathological examination to general situation, hematology, blood biochemical, the electrocardiogram of animal.2 weeks of drug withdrawal are not seen obvious change yet.Capsule of the present invention is not found overt toxicity reaction and delayed toxicity reaction in long term toxicity test.As seen, capsule non-toxic reaction of the present invention, long-term prescription is safe and reliable.
Conclusion: Capsules group of the present invention and XIPAYIMAIZIBIZI KOUFUYE group can improve lecithin density in the rat prostate, reduce leukocyte count; Obviously suppress dimethylbenzene induced mice ease auricle swelling; It is inhibited that the Dichlorodiphenyl Acetate induced mice is turned round body; To rat after administration in the 2h urine amount obviously increase; Can reduce whole blood viscosity and plasma viscosity, have the effect that improves hemorheological property; The inflammatory reaction that allergin (histamine, 5 one hydroxytryptamines) is caused has the obvious suppression effect; Urogenital sinus is implanted weight of prostate of prostatic hyperplasia mice and the effect that index has obvious reduction; Can alleviate the infiltration of inflammatory cell in weight of prostate and the lumen of gland; The activity and the Zn that can obviously suppress PACP in the hypertrophy rat blood serum of experimental prostatitis
2+Content.The result shows, capsule of the present invention than the antiinflammatory of XIPAYIMAIZIBIZI KOUFUYE, analgesia, diuresis, blood circulation promoting and blood stasis dispelling, to non-specific inflammatory reaction suppress, to the prostatitic inhibition of rat fibroplasia due to the xiaozhiling injection, to the inhibition of rat bacterial prostatitis, implant and bring out the prostatic hypertrophy of mice, effects such as anti-prostatic hyperplasia are obviously strengthened to alleviating urogenital sinus.As seen, the pharmacological action of capsule of the present invention is better than XIPAYIMAIZIBIZI KOUFUYE.
Clinical trial:
Clinical observation patient 318 examples of the present invention are used for the treatment of diseases of urinary system, outpatient's 227 examples wherein, inpatient's 91 examples.Wherein treat prostatitis 176 people, prostatic hyperplasia 142 people.Oral this product, one time 2,3 times on the one, take three courses of treatment after; Through clinical observation: total effective rate of the present invention is 93.5%, and its clinical efficacy is satisfied.After prostatitis patient uses this product, can thoroughly eliminate or alleviate anxious, hot, puckery, the pain symptom of urinating; The prostatic hyperplasia patient can improve soreness of the waist and knees, urine surplus energy, and clinical signs such as dizziness and tinnitus illustrate the exact efficacy of this product in the clinical observation process, do not find that the patient has untoward reaction and anaphylaxis, illustrate that this product is safe.
The specific embodiment of the invention:
The embodiment of the invention 1:
The prescription proportioning:
300 parts of 450 parts of Rhizoma Dioscoreae Septemlobaes of 450 portions of Semen Euryaless of Fructus Mori
100 parts of 200 parts of Brassica campestris L pollens of 250 portions of Fructus Gardeniaes of Fructus Rosae Laevigatae
The preparation method of capsule of the present invention: Fructus Mori, Semen Euryales, Fructus Rosae Laevigatae, Fructus Gardeniae four flavors, decoct with water 3 times, each decocted first, second time 2 hours with 8 times of water gagings, the 3rd time collecting decoction left standstill with 6 times of water gagings decoctions 1 hour, filter, filtrate decompression concentrate (0.08Mpa, 80 ℃) to the volume of crude drug than (1:1), standby; Rhizoma Dioscoreae Septemlobae is ground into coarse powder, adds 10 times of amount alcohol reflux 3 times, each 1 hour, filter, merging filtrate merges with above-mentioned reserve liquid, and adding ethanol is 70% to containing the alcohol amount, left standstill 24 hours, filter, filtrate recycling ethanol to relative density is 1.30～1.35 (80 ℃), 60 ℃ of dryings, be ground into fine powder, standby.Brassica campestris L pollen was pulverized 100 mesh sieves, with the abundant mixing of above-mentioned medicated powder; Add appropriate amount of starch, mixing incapsulates, and promptly gets Chinese medicinal capsule agent of the present invention.
The embodiment of the invention 2:
The prescription proportioning:
300 parts of 450 parts of Rhizoma Dioscoreae Septemlobaes of 450 portions of Semen Euryaless of Fructus Mori
100 parts of 200 parts of Brassica campestris L pollens of 250 portions of Fructus Gardeniaes of Fructus Rosae Laevigatae
The preparation method of granule of the present invention: Fructus Mori, Semen Euryales, Fructus Rosae Laevigatae, Fructus Gardeniae four flavors, decoct with water 3 times, each decocted first, second time 2 hours with 8 times of water gagings, the 3rd time collecting decoction left standstill with 6 times of water gagings decoctions 1 hour, filter, filtrate decompression concentrate (0.08Mpa, 80 ℃) to the volume of crude drug than (1:1), standby; The Mian CAOXIE is ground into coarse powder, adds 10 times of amount alcohol reflux 3 times, each 1 hour, filter, merging filtrate merges with above-mentioned reserve liquid, and adding ethanol is 70% to containing the alcohol amount, left standstill 24 hours, filter, filtrate recycling ethanol to relative density is 1.30～1.35 (80 ℃), 60 ℃ of dryings, be ground into fine powder, standby.Brassica campestris L pollen was pulverized 100 mesh sieves, with the abundant mixing of above-mentioned medicated powder; Add an amount of dextrin mixing, granulate, drying, pack promptly gets Chinese medicine granules of the present invention.
The embodiment of the invention 3:
The prescription proportioning:
300 parts of 450 parts of Mian CAOXIE of 450 portions of Semen Euryaless of Fructus Mori
100 parts of 200 parts of Brassica campestris L pollens of 250 portions of Fructus Gardeniaes of Fructus Rosae Laevigatae
The preparation method of tablet of the present invention: Fructus Mori, Semen Euryales, Fructus Rosae Laevigatae, Fructus Gardeniae four flavors, decoct with water 3 times, each decocted first, second time 2 hours with 8 times of water gagings, the 3rd time collecting decoction left standstill with 6 times of water gagings decoctions 1 hour, filter, filtrate decompression concentrate (0.08Mpa, 80 ℃) to the volume of crude drug than (1:1), standby; Rhizoma Dioscoreae Septemlobae is ground into coarse powder, adds 10 times of amount alcohol reflux 3 times, each 1 hour, filter, merging filtrate merges with above-mentioned reserve liquid, and adding ethanol is 70% to containing the alcohol amount, left standstill 24 hours, filter, filtrate recycling ethanol to relative density is 1.30～1.35 (80 ℃), 60 ℃ of dryings, be ground into fine powder, standby.Brassica campestris L pollen was pulverized 100 mesh sieves, with the abundant mixing of above-mentioned medicated powder; Add the appropriate amount of starch mixing, granulate, drying adds an amount of magnesium stearate mixing, and tabletting promptly gets Chinese medicinal tablet of the present invention.
Claims (6)
1, a kind of Chinese medicine preparation that is used for the treatment of prostatosis is characterized in that it is made up of the following weight proportion raw material:
Fructus Mori 300-500 part Semen Euryales 300-500 part Rhizoma Dioscoreae Septemlobae 200-400 part
Fructus Rosae Laevigatae 200-300 part Fructus Gardeniae 100-300 part Brassica campestris L pollen 50-150 part
2,, it is characterized in that each raw material optimum weight proportioning is according to the Chinese medicine preparation of the described treatment prostatosis of claim 1:
300 parts of 450 parts of Rhizoma Dioscoreae Septemlobaes of 450 portions of Semen Euryaless of Fructus Mori
100 parts of 200 parts of Brassica campestris L pollens of 250 portions of Fructus Gardeniaes of Fructus Rosae Laevigatae
3, according to claim 1 or 2 described Chinese medicine preparation, it is characterized in that: described Chinese patent medicine dosage form is granule, capsule, tablet.
4, according to the preparation method of the described Chinese medicine preparation of claim 3, it is characterized in that: Fructus Mori, Semen Euryales, Fructus Rosae Laevigatae, Fructus Gardeniae four flavors, decoct with water 3 times, each decocted first, second time 2 hours with 8 times of water gagings, and the 3rd time with 6 times of water gagings decoctions 1 hour, collecting decoction, leave standstill, filter, filtrate decompression concentrates (0.08Mpa, 80 ℃) to the volume of crude drug than (1:1), standby; Rhizoma Dioscoreae Septemlobae is ground into coarse powder, adds 10 times of amount alcohol reflux 3 times, each 1 hour, filter, merging filtrate merges with above-mentioned reserve liquid, and adding ethanol is 70% to containing the alcohol amount, left standstill 24 hours, filter, filtrate recycling ethanol to relative density is 1.30～1.35 (80 ℃), 60 ℃ of dryings, be ground into fine powder, standby.Brassica campestris L pollen was pulverized 100 mesh sieves, with the abundant mixing of above-mentioned medicated powder; Add appropriate amount of starch or dextrin, mixing is granulated, and drying gets preparation of the present invention.
According to claim 1 or 2 described Chinese medicine preparation, it is characterized in that 5, described preparation formulation is a capsule.
6, according to the preparation method of the described Chinese medicinal capsule agent of claim 5, it is characterized in that: Fructus Mori, Semen Euryales, Fructus Rosae Laevigatae, Fructus Gardeniae four flavors, decoct with water 3 times, each decocted first, second time 2 hours with 8 times of water gagings, and the 3rd time with 6 times of water gagings decoctions 1 hour, collecting decoction, leave standstill, filter, filtrate decompression concentrates (0.08Mpa, 80 ℃) to the volume of crude drug than (1:1), standby; Rhizoma Dioscoreae Septemlobae is ground into coarse powder, adds 10 times of amount alcohol reflux 3 times, each 1 hour, filter, merging filtrate merges with above-mentioned reserve liquid, and adding ethanol is 70% to containing the alcohol amount, left standstill 24 hours, filter, filtrate recycling ethanol to relative density is 1.30～1.35 (80 ℃), 60 ℃ of dryings, be ground into fine powder, standby.Brassica campestris L pollen was pulverized 100 mesh sieves, with the abundant mixing of above-mentioned medicated powder; Add appropriate amount of starch, mixing incapsulates, and promptly gets Chinese medicinal capsule agent of the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101675051A CN101361885B (en) | 2008-10-09 | 2008-10-09 | Chinese traditional medicine composition for treating the prostatitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101675051A CN101361885B (en) | 2008-10-09 | 2008-10-09 | Chinese traditional medicine composition for treating the prostatitis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101361885A true CN101361885A (en) | 2009-02-11 |
| CN101361885B CN101361885B (en) | 2011-01-12 |
Family
ID=40388613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101675051A Active CN101361885B (en) | 2008-10-09 | 2008-10-09 | Chinese traditional medicine composition for treating the prostatitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101361885B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810752A (en) * | 2010-05-06 | 2010-08-25 | 陕西康惠制药股份有限公司 | Method for detecting quality of Chinese medicament for treating prostatitis |
| CN102119939A (en) * | 2010-12-28 | 2011-07-13 | 周斌 | Angiosperm bee pollen water extract for treating fatty liver and preparation method and application thereof |
| CN105709014A (en) * | 2016-04-06 | 2016-06-29 | 陕西东泰制药有限公司 | Traditional Chinese medicine composition for treating prostatitis and prostatic hyperplasia and preparation method of traditional Chinese medicine composition |
-
2008
- 2008-10-09 CN CN2008101675051A patent/CN101361885B/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810752A (en) * | 2010-05-06 | 2010-08-25 | 陕西康惠制药股份有限公司 | Method for detecting quality of Chinese medicament for treating prostatitis |
| CN102119939A (en) * | 2010-12-28 | 2011-07-13 | 周斌 | Angiosperm bee pollen water extract for treating fatty liver and preparation method and application thereof |
| CN102119939B (en) * | 2010-12-28 | 2012-08-22 | 周斌 | Angiosperm bee pollen water extract for treating fatty liver and preparation method and application thereof |
| CN105709014A (en) * | 2016-04-06 | 2016-06-29 | 陕西东泰制药有限公司 | Traditional Chinese medicine composition for treating prostatitis and prostatic hyperplasia and preparation method of traditional Chinese medicine composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101361885B (en) | 2011-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107A (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN102058715B (en) | Chinese medicine preparation for treating chronic prostatitis and preparation method thereof | |
| CN102225181B (en) | Medicament for treating benign prostatic hyperplasia disease and preparation method thereof | |
| CN102988675B (en) | Traditional Chinese medicine combination for treating chronic prostatitis and preparation method thereof | |
| CN101361885B (en) | Chinese traditional medicine composition for treating the prostatitis and preparation method thereof | |
| CN101721528B (en) | Medicine composition for treating chronic prostatitis | |
| CN102908579A (en) | Traditional Chinese medicine preparation for treating gynecological diseases, liver diseases and prostatitis and preparation method of traditional Chinese medicine preparation | |
| CN109692309A (en) | Treat nonalcoholic fatty liver eliminating toxic dampness and heat side | |
| CN101732662B (en) | Chinese medicinal composition for treating pelvic inflammatory disease and preparation method thereof | |
| CN101317881A (en) | Traditional Chinese medicine compound and formulation for removing renal stone | |
| CN104491101B (en) | Preparing method of traditional Chinese medicine preparation for treatment of chronic renal failure | |
| CN100425252C (en) | Medicine for treating leukopenia | |
| CN100460001C (en) | Chinese medicinal composition for treating chronic prostate and its preparation | |
| CN101695532A (en) | Medicament for treating prostate disease and preparation process thereof | |
| CN101229238B (en) | Chinese traditional medicine preparation for treating prostate disease | |
| CN1327874C (en) | Chinese medicine formulation for treating chronic prostatitis and its preparing method | |
| CN101485847B (en) | Chinese medicinal composition for treating prostatic diseases and preparation method thereof | |
| CN115040576B (en) | Pharmaceutical composition for treating acute pancreatitis | |
| CN103656312B (en) | Traditional Chinese medicinal composition for treating urinary retention after colorectal surgery | |
| CN101618118B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating cystitis | |
| CN103417714B (en) | Traditional Chinese medicine composition used for prostate diseases | |
| CN103285131B (en) | Chinese medicine lotion for treating mastitis | |
| CN100441205C (en) | Medicine for treating blood system disease | |
| CN100408085C (en) | Snow lotus preparation for treating prostate disease | |
| CN1242772C (en) | Chinese medicine for hemorrhoid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |